|Bid||0.00 x 800|
|Ask||0.00 x 1300|
|Day's Range||118.09 - 121.67|
|52 Week Range||100.15 - 159.89|
|Beta (5Y Monthly)||0.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2023 - Nov 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||180.94|
Subscribe to Yahoo Finance Plus to view Fair Value for SRPT
CAMBRIDGE, Mass., September 29, 2023--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 29, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in September 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(
The big names behind biotech stocks no longer want to merely treat diseases, they want to cure them. But it's going to be costly.
Here are two companies to consider: Sarepta Therapeutics (NASDAQ: SRPT) and Shopify (NYSE: SHOP). Sarepta Therapeutics is a biotech company that focuses on developing medicines for rare diseases. Sarepta Therapeutics' portfolio of DMD therapies is generating consistently growing sales.